These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 2642538)

  • 21. Quality of life in clinical trials of adjuvant therapies. International Breast Cancer Study Group (formerly Ludwig Group).
    Gelber RD; Goldhirsch A; Hürny C; Bernhard J; Simes RJ
    J Natl Cancer Inst Monogr; 1992; (11):127-35. PubMed ID: 1385719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A quality-of-life-oriented endpoint for comparing therapies.
    Gelber RD; Gelman RS; Goldhirsch A
    Biometrics; 1989 Sep; 45(3):781-95. PubMed ID: 2790121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer.
    Bernhard J; Zahrieh D; Zhang JJ; Martinelli G; Basser R; Hürny C; Forbes JF; Aebi S; Yeo W; Thürlimann B; Green MD; Colleoni M; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Coates AS;
    Br J Cancer; 2008 Jan; 98(1):25-33. PubMed ID: 18043579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating treatment strategies in advanced Waldenström macroglobulinemia: use of quality-adjusted survival analysis.
    Lévy V; Porcher R; Leblond V; Fermand JP; Cazin B; Maloisel F; Harousseau JL; Remenieras L; Guibon O; Chevret S;
    Leukemia; 2001 Sep; 15(9):1466-70. PubMed ID: 11516109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
    Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
    N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.
    Kuru B; Camlibel M; Dinc S; Gulcelik MA; Atalay C; Alagol H
    J Exp Clin Cancer Res; 2005 Sep; 24(3):363-72. PubMed ID: 16270522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
    Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M
    J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term survival outcomes following internal mammary node irradiation in stage II-III breast cancer: results of a large retrospective study with 12-year follow-up.
    Chang JS; Park W; Kim YB; Lee IJ; Keum KC; Lee CG; Choi DH; Suh CO; Huh SJ
    Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):867-72. PubMed ID: 23747215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.
    Pagani O; Gelber S; Simoncini E; Castiglione-Gertsch M; Price KN; Gelber RD; Holmberg SB; Crivellari D; Collins J; Lindtner J; Thürlimann B; Fey MF; Murray E; Forbes JF; Coates AS; Goldhirsch A;
    Breast Cancer Res Treat; 2009 Aug; 116(3):491-500. PubMed ID: 18953651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
    Muss HB; Tu D; Ingle JN; Martino S; Robert NJ; Pater JL; Whelan TJ; Palmer MJ; Piccart MJ; Shepherd LE; Pritchard KI; He Z; Goss PE
    J Clin Oncol; 2008 Apr; 26(12):1956-64. PubMed ID: 18332474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
    Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
    Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. International Breast Cancer Study Group.
    Gelber RD; Goldhirsch A; Cole BF
    Control Clin Trials; 1993 Dec; 14(6):485-99. PubMed ID: 8119064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consensus conference. Adjuvant chemotherapy for breast cancer.
    JAMA; 1985 Dec; 254(24):3461-3. PubMed ID: 4068189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice.
    Bonifazi M; Franchi M; Rossi M; Zambelli A; Moja L; Zambon A; Corrao G; La Vecchia C; Zocchetti C; Negri E
    Breast; 2014 Oct; 23(5):573-8. PubMed ID: 24934637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma.
    Zee B; Cole B; Li T; Browman G; James K; Johnston D; Sugano D; Pater J
    J Clin Oncol; 1998 Aug; 16(8):2834-9. PubMed ID: 9704736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A single perioperative adjuvant chemotherapy course for node-negative breast cancer: five-year results of trial V. International Breast Cancer Study Group (formerly Ludwig Group).
    Goldhirsch A; Castiglione M; Gelber RD
    J Natl Cancer Inst Monogr; 1992; (11):89-96. PubMed ID: 1627436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant radiation after modified radical mastectomy for breast cancer fails to prolong survival.
    Geisler DP; Boyle MJ; Malnar KF; Melichar RM; McGee JM; Nolen MG; Broughan TA
    Am Surg; 2000 May; 66(5):452-8; discussion 458-9. PubMed ID: 10824745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer.
    Camoriano JK; Loprinzi CL; Ingle JN; Therneau TM; Krook JE; Veeder MH
    J Clin Oncol; 1990 Aug; 8(8):1327-34. PubMed ID: 2199619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive value of Ki67 for adjuvant chemotherapy in node-negative, hormone receptor-positive breast cancer.
    Sutepvarnon A; Warnnissorn M; Srimuninnimit V
    J Med Assoc Thai; 2013 Feb; 96 Suppl 2():S60-6. PubMed ID: 23590023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose chemotherapy for patients with high-risk breast cancer: a clinical and economic assessment using a quality-adjusted survival analysis.
    Marino P; Roché H; Moatti JP;
    Am J Clin Oncol; 2008 Apr; 31(2):117-24. PubMed ID: 18391594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.